Great News for Eli Lilly Stock Investors
Key PointsEli Lilly's tirzepatide is showing potential across autoimmune diseases.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.